Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
We have generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells.
Our SPEAR T-cell therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. Adaptimmune partners with industry leaders in all areas of it's business.
Responses in 4 new solid tumor indications
100% reduction in target lesions in first patient treated with ADP-A2AFP in Cohort 3
Partnership with Astellas to develop allogeneic cell therapies
~$90m raised via secondary public offering
Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors with ADP-A2M4, ADP-A2M10, ADP-A2AFP
SPEARHEAD-1 study started 2H19 (synovial sarcoma and MRCLS)
SURPASS (first next gen candidate) started 2H19
Collaboration with Alpine Immune Sciences
Registered Direct Offering (RDO) of ~$100M
Transition of NY-ESO SPEAR T-cell Therapy Program to GSK complete
Opening of UK Vector Manufacturing Facility at Catapult in Stevenage
Breakthrough therapy designation and PRIME regulatory access for NY-ESO SPEAR T-cell therapy
*NY-ESO program was transitioned to GSK in August 2018.
TCR technology developed at Oxford University
Avidex was formed on the basis of T cell receptor technology from Oxford University
Avidex was acquired by Medigene
Adaptimmune spun out as a virtual company with University of Penn collaboration
Adaptimmune establishes R&D infrastructure and delivers promising clinical data
Strategic collaboration with GSK + $104m Series A Funding Round